Lloyd Damon
Overview
Explore the profile of Lloyd Damon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
936
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee A, Badgley C, Lo M, Banez M, Graff L, Damon L, et al.
Bone Marrow Transplant
. 2023 Aug;
58(11):1247-1253.
PMID: 37626267
Hematopoietic cell transplant (HCT) recipients are at risk for thromboembolic and bleeding complications. There is limited evidence regarding the optimal approach to managing venous thromboembolism (VTE) prophylaxis in hospitalized patients...
2.
Trinh T, Strnad L, Damon L, Dzundza J, Graff L, Griffith L, et al.
Infect Control Hosp Epidemiol
. 2021 Jan;
42(9):1090-1097.
PMID: 33487182
Objective: To evaluate broad-spectrum intravenous antibiotic use before and after the implementation of a revised febrile neutropenia management algorithm in a population of adults with hematologic malignancies. Design: Quasi-experimental study....
3.
Valliani S, Ali M, Mahmoo O, Hinduja S, Chen C, Damon L, et al.
Case Rep Hematol
. 2021 Jan;
2020:8823877.
PMID: 33425404
Primary plasma cell leukemia (pPCL) is an uncommon disease. IgM multiple myeloma (MM) is an infrequent subtype that accounts for less than 1 percent of MM cases. IgM pPCL is...
4.
Thiruvengadam S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai W, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Dec;
21(4):246-256.e2.
PMID: 33288485
Background: More than one-half of high-risk patients with relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) relapse after autologous hematopoietic cell transplantation (auto-HCT). In this phase II study, we investigate the...
5.
Ko A, Jordan A, Tooker E, Lacey S, Chang R, Li Y, et al.
Mol Ther
. 2020 Jul;
28(11):2367-2378.
PMID: 32730744
B cells infiltrate pancreatic ductal adenocarcinoma (PDAC) and in preclinical cancer models, can suppress T cell immunosurveillance in cancer. Here, we conducted a pilot study to assess the safety and...
6.
Burns S, Damon L, Akagi N, Laszik Z, Ko A
Anticancer Res
. 2020 Jul;
40(7):3995-4000.
PMID: 32620643
We present here the case of a 39-year-old man with metastatic pancreatic carcinoma receiving chemotherapy with the combination of gemcitabine and nab-paclitaxel as part of a clinical trial. Despite an...
7.
Gupta S, Damon L, Gelfand J
JAMA Neurol
. 2019 Sep;
76(11):1397-1398.
PMID: 31524939
No abstract available.
8.
Mule M, Mannis G, Wood B, Radich J, Hwang J, Ramos N, et al.
Biol Blood Marrow Transplant
. 2016 Aug;
22(11):1974-1982.
PMID: 27544285
We report here the largest study to date of adult patients with acute myeloid leukemia (AML) tested for measurable residual disease (MRD) at the time of autologous hematopoietic cell transplantation...
9.
Ravandi F, Ritchie E, Sayar H, Lancet J, Craig M, Vey N, et al.
Lancet Oncol
. 2015 Aug;
16(9):1025-1036.
PMID: 26234174
Background: Safe and effective treatments are urgently needed for patients with relapsed or refractory acute myeloid leukaemia. We investigated the efficacy and safety of vosaroxin, a first-in-class anticancer quinolone derivative,...
10.
Marra J, Greene J, Hwang J, Du J, Damon L, Martin T, et al.
J Immunol
. 2015 Mar;
194(9):4222-30.
PMID: 25810393
Killer cell Ig-like receptors (KIRs) bind cognate HLA class I ligands with distinct affinities, affecting NK cell licensing and inhibition. We hypothesized that differences in KIR and HLA class I...